A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma - Trial NCT06118333
Access comprehensive clinical trial information for NCT06118333 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 368 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan Baili Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 3
Nov 01, 2023
Dec 01, 2025
Primary Outcome
Objective Response Rate (ORR),Overall survival (OS)
Summary
A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of
 BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at
 least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody
 as the last line of therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06118333
Non-Device Trial